Inactivated influenza virus vaccines (IVVs) are used for prevention of influenza and its complications. Present vaccines are immunogenic, of low reactogenicity, and protective, but protection has varied between 0% and 100%. Increasing the dose of hemagglutinin and neuraminidase antigens with purified proteins significantly increased serum and nasal antibody responses; however, trials with newer adjuvants have not shown increased serum antibody to levels comparable with those in earlier studies using oil emulsion adjuvants. IgA antibody responses in respiratory secretions were enhanced by the respiratory administration of IVVs, but IVVs by the oral route yielded varying results. IVVs appeared less effective for pandemic influenza in 1968 than in 1957. Since IVVs will be the major preventative measure for pandemic influenza in most countries, they need to be improved to provide better protection against pandemic and interpandemic influenza. Increasing the doses of hemagglutinin and neuraminidase, using adjuvants or immunomodulators, and administering IVVs by the mucosal route could improve the performance of these vaccines.
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Inactivated influenza virus vaccines (IVVs) were approved for rized in table 1. It was shown early that chick embryo -grown use in humans Ç50 years ago. Since that time, they have been virus was a satisfactory source of virus for vaccine and that used with success for prevention of influenza by the military and formaldehyde treatment preserved antigenicity while destroyamong civilians at high risk for development of severe disease ing infectivity. Demonstration that serum antibody responses and life-threatening complications from infection [1] . The latter to vaccine were followed by protection against an infectious group include elderly persons and those with a number of chronic challenge was provided shortly thereafter. After it was shown conditions. Although a recommendation for annual use of vaccine that virus hemagglutination and that antibody responses can be in these populations was in place for decades, vaccination rates measured in hemagglutination-inhibition (HAI) tests, quantitawere relatively low until about 1990 [2] . In recent years, doses tive hemagglutination assays became the potency standard for prepared by manufacturers for the US population and rates of vaccine preparations. Reactogenicity of vaccine preparations, immunization among high-risk persons have progressively inparticularly early vaccines, was directly related to dose. Splitcreased (Williams M, personal communication) . This is occurring product vaccines were developed primarily to reduce this reacwithout a change in the properties of available vaccines; they togenicity [3] , and various other means for removal of nonviral have been basically the same (except for periodic change in anticontaminants of vaccine preparations were introduced to reduce gens) for more than a decade. At present, these vaccines are the reactogenicity. most commonly used vaccines in the United States and most Reports on the numerous factors that can influence immunoother developed countries. Moreover, they are currently the major genicity probably make IVVs the most studied vaccines over potential preventative for pandemic influenza. It is important that the past 50 years (table 1) . Properties of the vaccines as well efforts to improve IVVs continue so that both the record and the as characteristics of the host have been thoroughly assessed. reputation of their value are unquestioned.
Of note in these numerous reports are the repeated demonstrations of increasing serum HAI antibody responses with increasVaccine Evolution ing vaccine dose, the requirement for at least two doses for satisfactory responses among unprimed persons, and that both IVVs have evolved over the decades since their introduction humoral and cellular systemic immune responses and antibody into public health. Lowest protection levels were seen among children 3 -5 years
Cell-mediated immune response of age, and the highest levels were seen among healthy adolesMucosal immunizations cents and young adults. In addition, lower protection rates were seen more often when the epidemic virus was heterotypic to the vaccine virus. Thus, although effective for prevention of infection with an influenza virus, vaccine-induced protection infection varies considerably for the different epidemics, and this variation is partly explained by these antigenic differences may be low. between vaccine and epidemic virus.
There are a number of recurring findings over the decades Mediators of Immunity of study that deserve emphasis when considering improvement of inactivated vaccines. Among these are that purification re-
A consideration of what is needed to improve effectiveness duces reactogenicity; immunogenicity can be improved; and of IVVs must focus on our understanding of mediators of protection against infection and illness, which is frequently immunity to influenza virus infection. Vaccine-induced prevenlow, regularly follows vaccination. Clearly, an opportunity for tion of infection requires induction of antibody to the viral improving IVVs exists. While this is desirable at present, it hemagglutinating protein (HA) in both serum and respiratory could be necessary for satisfactory effectiveness in the face of secretions [10, 11] . A reduction in intensity of infection so that pandemic influenza. illness does not occur or is ameliorated is the primary function of antibody to the neuraminidase (NA) antigen, although anti-HA antibody can exhibit a similar function [12, 13] . An early Current Vaccines T cell cytotoxic (CTL) response could also contribute toward reducing the intensity of the infection, but at present, its major The major deficiency of current vaccines is that the protection they induce is less than desirable; it may be high among healthy adult populations but is generally lower among young role is considered to be mediation of recovery from the infecresponses among healthy young adults given recombinant DNA -produced HA vaccines were followed by evidence of tion [10, 11] . Other specific immune mechanisms, such as antibody-dependent cell cytotoxicity and nonspecific immune meprotection against natural infection in the vaccinated group. We have also evaluated purified NA vaccines in a similar diators (e.g., interferon), undoubtedly contribute to control of the infection.
manner among healthy young adults [20] . Doses of 2.6 -69.6 mg of NA increased frequencies of serum NA-inhibiting antiParenteral administration of IVV leads to induction of anti-HA and anti-NA antibody in both serum and respiratory secrebody responses from 40% to 90% and ELISA antibody from 15% to 80%. Frequencies for a commercial vaccine containing tions. An increase in T cell cytotoxicity that can be stimulated in vitro can also follow administration of IVV among adults an estimated 7 mg of NA protein were 60% for NA-inhibiting antibody and 55% for ELISA responses. and children [14, 15] . Although higher CTL responses have corresponded with reduced viral shedding, a persisting and
Thus, it appears that highly pure vaccine preparations of HA and NA can be safely given in increased doses and that these beneficial effect of this response has not been demonstrated in humans vaccinated with IVV [16] . Thus, at present, the focus increased doses induce increased frequencies and levels of anti-HA and anti-NA antibodies. Moreover, this increase in refor an early improvement in IVV is on increasing the anti-HA and anti-NA antibody responses.
sponse in relation to dose persisted for months after vaccination. Of interest is that an increase in antigen dose does not lead to a proportionate increase in the antibody response, an Improving IVVs observation made in earlier studies [21, 22] . Whether these increases in antibody lead to increased protection is yet to be Major options for improving IVVs in the near future include purification of subunits and production of pure proteins via shown; however, similar dose-related increases have done so in the past [21] . recombinant DNA technology so as to permit administration of increased doses of HA and NA without encountering significant Adjuvants and immunomodulators. Adjuvants substantially enhanced serum HAI antibody responses of vaccines used reactogenicity; the use of adjuvants to increase immune responses; the use of immunomodulators to enhance or restore during the 1940s and 1950s; both alum and water in oil emulsions were used [23 -27]. Large numbers of military recruits optimal immune responses, particularly for elderly and immunocompromised persons; and the addition of mucosal adminiswere given IVV in mineral oil adjuvant, and significant increases in serum antibody titers occurred. However, although tration so as to improve the induction of secretory IgA antibody and the amount of antibody in respiratory secretions.
infrequent, occurrences of sterile abscesses at the site of injection led to discontinuation of the use of these vaccines. An Dose. We have recently reevaluated increasing the dose of HA, using purified HA vaccine preparations provided by alternative, highly immunogenic adjuvant emulsion (adjuvant 65) was never adopted for general use [26] . Recent studies Pasteur-Mérieux -Connaught Laboratories (Swiftwater, PA). Figure 1 shows serum neutralizing antibody responses to with IVV, using newer adjuvants, have not shown increased magnitudes of antibody responses similar to those reported graded doses of HA in an A/Taiwan/86 (H1N1) vaccine given once intramuscularly to healthy college students [17] . As noted, earlier. Incorporation of an A/H1N1 antigen in liposomes induced little to no increase in antibody responses compared with a direct correlation was detected between dose and mean titer that persisted for 24 weeks among persons selected for little responses from standard vaccine among either young adults (Cate TR, unpublished data) or elderly persons [28] . A new or no prevaccination serum antibody as well as those selected for presence of high titers. Of interest is that a maximal reoil-and-water emulsion using squalene and detergents (MF59) enhanced serum HAI antibody responses in the elderly, but sponse was not identified. The proportion of students with a rise in specific antibody in nasal wash (NW) specimens at 2 mean responses were usually õ2-fold [29] . Human trials have also used Qs21 (a derivative of saponin) and monophosphoryl weeks is shown in figure 2 . The proportion of both IgA and IgG antibody responses increased with increasing vaccine dose.
lipid A, but results have not been reported. Finally, in a small group of volunteers, a derivative of muramyl dipeptide, the Minimal reactogenicity was noted for these preparations.
The same vaccine preparation was given at the 15-, 45-, and adjuvant fraction of mycobacteria, induced major reactions that appeared to have a multicomponent explanation [30] . Thus, 135-mg dose levels to healthy persons ú65 years old (mean, 72) along with similar doses of split-product vaccine [18] . With addition of a number of newer adjuvants to IVVs has not yet led to increases in serum antibody responses comparable to increasing doses, each vaccine induced an increase in serum HAI or neutralizing antibody and IgG or IgA antibody in nasal those reported decades ago. In addition, reports of enhanced antibody responses among washes. Between the 15-and 135-mg doses, both serum and nasal wash response frequencies doubled, and mean titers inelderly persons given thymosin a 1 along with IVV suggests value from adding an immunomodulator for enhancing (or recreased 2-to 3-fold. The split-product vaccines were somewhat more reactogenic, a finding that could restrict formulation of storing) immune responses among selected populations [31] . A great variety of adjuvants and immunomodulators have trivalent preparations at the 135-mg dose level for each of 3 virus strains. In a study by Powers et al. [19] in animal models. Despite the lack of a major enhancing effect descent into the lower respiratory tract, the proportion of immunoglobulin that is IgG increases. Reynolds et al.
[34] reported in recent human studies, it remains possible that one or more of these immune-enhancing agents will prove of value in humans.
that about one-third of the immunoglobulin recovered in secretions from lower respiratory passages was IgA and two-thirds Adjuvants could be of particular value in a pandemic circumstance either for the large number of persons who would be was IgG. In quantitations of specific influenza virus antibody, we found that a higher proportion of the antibody was IgG in unprimed or as a means of conserving antigen that is available in limited quantities.
both nasal and lower respiratory secretions [11] . It should be noted that IgG antibody in secretions is derived primarily from Mucosal administration. The need for protective levels of specific antibody in respiratory secretions for prevention of circulating IgG antibody, while IgA antibody is derived primarily from local lymphoid tissues [33] . influenza virus infection was emphasized by Francis [32] ú50 years ago. Current knowledge of immunoglobulin occurrences Available data indicate that the airborne route is the primary in respiratory secretions indicates that there is variation in conmeans for spread of influenza [11] . When breathing is through centrations of the different isotypes within the respiratory systhe nose, virus is about equally likely to deposit initially in the tem. IgA antibody is dominant in nasal secretions, generally lower or the upper respiratory passages. This probability, in constituting Ç90% of the immunoglobulin present [33] . With combination with the apparent increased susceptibility of the lower tract, suggests that most cases of influenza are initiated in the lower tract [11] . Since the dominant immunoglobulin in secretions at this site is IgG, which is derived primarily from serum, serum IgG antibody appears to be the most important antibody for providing protection against influenza. Nevertheless, infection of the upper respiratory tract could occur initially as well as secondarily to infection in the lower tract; therefore, it is also desirable to induce IgA antibody at this site in quantities sufficient for prevention of infection. Following the description of the mucosal immune system for secretion of IgA antibody, a number of studies of antibody responses in respiratory secretions were conducted. In the 1970s, studies indicated that the intranasal administration of IVV ensured the occurrence of antibody in nasal secretions of elderly persons and enhanced levels among seropositive persons [35 -37] . A combination of parenteral and intranasal administration appeared to be optimal for inducing antibody in More recently, considerable attention has been brought to weeks) in relation to vaccine dose. High and low prevaccination antibody groups in figure 1 were combined. From data in [17] . [43] . Depopulation groups and is sometimes low. Moreover, there is pending upon the uniqueness of the HA and NA, IVV for a experience available from prior pandemics suggesting that new pandemic virus could require two doses for satisfactory IVVs may be even less effective in pandemic situations than immunization of substantial portions of the world's population.
in interpandemic epidemic outbreaks. Since IVV will constitute For this reason, current developmental efforts that would obvia major component of any pandemic response in the near future, ate this potential problem deserve attention. Efforts such as improvement of current vaccines is needed for both pandemic adjuvant development that could lead to satisfactory immune and interpandemic epidemic influenza. There are a number of responses with lower doses of antigen would decrease the buroptions for improvement of the protective capacity of IVVs in den of vaccine production. Alternatively, an increase in producthe near future that are deserving of effort, including increasing tion capability by industry could lessen the supply problem, an item being addressed in current pandemic planning. In both instances, current approaches to improve influenza vaccines Table 3 . Efficacy of inactivated influenza virus vaccine for panduring interpandemic periods should relate to our ability to demic A/Hong Kong (H3N2) influenza -randomized studies.
respond to the threat of pandemic influenza.
Of greater concern than vaccine supply are the data suggesting 
